AGMB-447 is an inhaled small molecule lung-restricted inhibitor of ALK5 (of TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Idiopathic Pulmonary Fibrosis (IPF) is a devastating disease affecting over 300,000 patients worldwide. IPF is characterized by unregulated production of fibrotic, scar-like tissue that builds up in the scaffolding of the lungs. As a result, the fibrotic lung becomes stiff, hampers the patient’s ability to breathe and reduces the absorption of inhaled oxygen in the blood. Even though some medicinal treatments are available, without a lung transplant, the average survival following diagnosis is only 3-5 years. In IPF, TGFβ is a master regulator of key disease mechanisms and early clinical data supports this role. AGMB-447 is specifically designed to inhibit ALK5 in the respiratory tract while avoiding clinically relevant systemic exposure through rapid hydrolyzation in the bloodstream. Through AGMB-447, Agomab aims to reverse fibrosis in these patients.

AGMB-447 is currently being investigated in a Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants with IPF (NCT06181370)